229 related articles for article (PubMed ID: 22352453)
1. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition.
Eissing T; Lippert J; Willmann S
Mol Diagn Ther; 2012 Feb; 16(1):43-53. PubMed ID: 22352453
[TBL] [Abstract][Full Text] [Related]
2. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
4. Codeine and morphine pathway.
Thorn CF; Klein TE; Altman RB
Pharmacogenet Genomics; 2009 Jul; 19(7):556-8. PubMed ID: 19512957
[No Abstract] [Full Text] [Related]
5. Lack of impairment due to confirmed codeine use prior to a motor vehicle accident: role of pharmacogenomics.
Wu AH; Kearney T
J Forensic Leg Med; 2013 Nov; 20(8):1024-7. PubMed ID: 24237812
[TBL] [Abstract][Full Text] [Related]
6. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.
Lötsch J; Skarke C; Schmidt H; Rohrbacher M; Hofmann U; Schwab M; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):35-48. PubMed ID: 16413240
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.
Court MH; Krishnaswamy S; Hao Q; Duan SX; Patten CJ; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Sep; 31(9):1125-33. PubMed ID: 12920168
[TBL] [Abstract][Full Text] [Related]
8. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
[TBL] [Abstract][Full Text] [Related]
9. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.
Vevelstad M; Pettersen S; Tallaksen C; Brørs O
Eur J Clin Pharmacol; 2009 Aug; 65(8):795-801. PubMed ID: 19308365
[TBL] [Abstract][Full Text] [Related]
10. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.
Gelston EA; Coller JK; Lopatko OV; James HM; Schmidt H; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 May; 73(5):786-94. PubMed ID: 22092298
[TBL] [Abstract][Full Text] [Related]
11. Codeine analgesia is due to codeine-6-glucuronide, not morphine.
Vree TB; van Dongen RT; Koopman-Kimenai PM
Int J Clin Pract; 2000; 54(6):395-8. PubMed ID: 11092114
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode.
Takeda S; Kitajima Y; Ishii Y; Nishimura Y; Mackenzie PI; Oguri K; Yamada H
Drug Metab Dispos; 2006 Aug; 34(8):1277-82. PubMed ID: 16679387
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the in vitro CYP450 mediated metabolism of the polymorphic CYP2D6 probe drug codeine in horses.
Knych HK; Baden RW; Gretler SR; McKemie DS
Biochem Pharmacol; 2019 Oct; 168():184-192. PubMed ID: 31295464
[TBL] [Abstract][Full Text] [Related]
14. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Wu X; Yuan L; Zuo J; Lv J; Guo T
Eur J Clin Pharmacol; 2014 Jan; 70(1):57-63. PubMed ID: 24077935
[TBL] [Abstract][Full Text] [Related]
15. Codeine intoxication associated with ultrarapid CYP2D6 metabolism.
Gasche Y; Daali Y; Fathi M; Chiappe A; Cottini S; Dayer P; Desmeules J
N Engl J Med; 2004 Dec; 351(27):2827-31. PubMed ID: 15625333
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 phenotype-specific codeine population pharmacokinetics.
Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
19. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4.
Takeda S; Ishii Y; Iwanaga M; Mackenzie PI; Nagata K; Yamazoe Y; Oguri K; Yamada H
Mol Pharmacol; 2005 Mar; 67(3):665-72. PubMed ID: 15611481
[TBL] [Abstract][Full Text] [Related]
20. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine.
Madadi P; Koren G; Cairns J; Chitayat D; Gaedigk A; Leeder JS; Teitelbaum R; Karaskov T; Aleksa K
Can Fam Physician; 2007 Jan; 53(1):33-5. PubMed ID: 17872605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
